Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 10/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057805 | 1.00 | SMO (0.45) | SMONR3C1MAPK1MEN1POLB | |
| SCHEMBL21058051 | 1.00 | SMO (0.45) | SMONR3C1MAPK1MEN1POLB | |
| SCHEMBL21057753 | 1.00 | SMO (0.45) | SMONR3C1MAPK1MEN1POLB | |
| SCHEMBL25997743 | 0.88 | SMO (0.45) | SMONR3C1MAPK1 | |
| SCHEMBL29526194 | 0.88 | SMO (0.45) | SMONR3C1MAPK1 | |
| SCHEMBL21057899 | 0.88 | SMO (0.45) | SMONR3C1MAPK1 | |
| SCHEMBL22572831 | 0.88 | SMO (0.45) | SMONR3C1MAPK1 | |
| SCHEMBL21058104 | 0.85 | SMO (0.50) | SMONR3C1MAPK1 | |
| SCHEMBL24282902 | 0.85 | SMO (0.46) | SMONR3C1MAPK1 | |
| SCHEMBL21104148 | 0.83 | NR3C1 (0.44) | SMONR3C1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344605-B2 | Substituted pyrrolidine amides II | GRUENENTHAL GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3728233-B1 | SUBSTITUTED PYRROLIDINE AMIDES II | GRUENENTHAL GMBH (DE) | 2022-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127264-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | NR3C1, NR3C2, MC2R | SMO 4592/4885NR3C1 1/4885MAPK1 1217/4885 |
| US-12344605-B2 | Substituted pyrrolidine amides II | NR3C1, NR3C2, MC2R | SMO 4592/4885NR3C1 1/4885MAPK1 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.